Related Experiment Video

Updated: Oct 1, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.3K

The Role of Antiplatelet Therapy in Patients With MINOCA

Luis Ortega-Paz1,2, Mattia Galli1,3, Davide Capodanno4

  • 1Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, United States.

Frontiers in Cardiovascular Medicine
|March 3, 2022
PubMed

Insights

Platelets are key in heart attacks with blocked arteries. Their role in myocardial infarction with non-obstructive coronary arteries (MINOCA) is unclear, impacting antiplatelet therapy use.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Platelet Physiology

Background:

  • Myocardial infarction with non-obstructive coronary arteries (MINOCA) presents a diagnostic challenge.
  • Platelets are crucial in obstructive coronary artery disease but their role in MINOCA is less understood.
  • Current antiplatelet therapy guidelines for myocardial infarction (MI) may not fully apply to MINOCA.

Purpose of the Study:

  • To review the role of platelets in the pathophysiology of MINOCA.
  • To evaluate the current evidence and future directions for antiplatelet therapy in MINOCA.
  • To explore therapeutic targets related to platelet function in MINOCA.

Main Methods:

  • Literature review focusing on platelet involvement in MINOCA.
  • Analysis of current clinical evidence regarding antiplatelet agents in MINOCA.
  • Examination of different MINOCA etiologies and their relation to platelet activation.

Main Results:

  • The precise role of platelets in MINOCA pathophysiology requires further elucidation.
  • Evidence supporting routine antiplatelet therapy in all MINOCA patients is limited.
  • Understanding MINOCA subtypes is crucial for tailoring antiplatelet strategies.

Conclusions:

  • Antiplatelet therapy's role in MINOCA is complex and etiology-dependent.
  • Further research is needed to define optimal antiplatelet strategies for MINOCA.
  • Personalized approaches considering platelet function may benefit MINOCA patients.
Keywords:
antiplatelet therapyatherosclerotic plaquecoronary artery disease non-obstructivecoronary vasospasmdual anti-platelet therapymicrovascular diseasemyocardial infarctionspontaneous coronary artery dissection

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.1K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
673
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
44
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
52
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
40
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
43